Zobrazeno 1 - 10
of 201
pro vyhledávání: '"Clare Sun"'
Autor:
Jennifer R. Brown, John C. Byrd, Paolo Ghia, Jeff P. Sharman, Peter Hillmen, Deborah M. Stephens, Clare Sun, Wojciech Jurczak, John M. Pagel, Alessandra Ferrajoli, Priti Patel, Lin Tao, Nataliya Kuptsova-Clarkson, Javid Moslehi, Richard R. Furman
Publikováno v:
Haematologica, Vol 107, Iss 6 (2021)
Cardiovascular (CV) toxicities of the Bruton tyrosine kinase (BTK) inhibitor ibrutinib may limit use of this effective therapy in patients with chronic lymphocytic leukemia (CLL). Acalabrutinib is a second-generation BTK inhibitor with greater BTK se
Externí odkaz:
https://doaj.org/article/539d278310f84aa3955bb4b7eb5f3b1d
Autor:
Anfal Alsadhan, Jonathan Chen, Erika M. Gaglione, Chingiz Underbayev, Pamela L. Tuma, Xin Tian, Lita A. Freeman, Sivasubramanian Baskar, Pia Nierman, Susan Soto, Andy Itsara, Inhye E. Ahn, Clare Sun, Elena Bibikova, Tanja Nicole Hartmann, Maissa Mhibik, Adrian Wiestner
Publikováno v:
Clinical Cancer Research. :OF1-OF10
Purpose: To determine the role of CD49d for response to Bruton's tyrosine kinase inhibitors (BTKi) in patients with chronic lymphocytic leukemia (CLL). Patients and Methods: In patients treated with acalabrutinib (n = 48), CD49d expression, VLA-4 int
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::4420625cc2652fac64c46a0fd8af1ff4
https://doi.org/10.1158/1078-0432.ccr-22-3217
https://doi.org/10.1158/1078-0432.ccr-22-3217
Autor:
Dan A. Landau, Clare Sun, Daniel Rosebrock, Sarah E. M. Herman, Joshua Fein, Mariela Sivina, Chingiz Underbayev, Delong Liu, Julia Hoellenriegel, Sarangan Ravichandran, Mohammed Z. H. Farooqui, Wandi Zhang, Carrie Cibulskis, Asaf Zviran, Donna S. Neuberg, Dimitri Livitz, Ivana Bozic, Ignaty Leshchiner, Gad Getz, Jan A. Burger, Adrian Wiestner, Catherine J. Wu
Publikováno v:
Nature Communications, Vol 8, Iss 1, Pp 1-12 (2017)
In a subset of patients with chronic lymphocytic leukemia (CLL) treated with targeted agents, such as ibrutinib, drug resistant subclones emerge. Here, the authors report on transcriptional changes in CLL patients treated with ibrutinib and identify
Externí odkaz:
https://doaj.org/article/8cb0dbf9095d4ad38df29729f10e5da6
Autor:
Anthony R. Mato, William G. Wierda, Weiyun Z. Ai, Ian W. Flinn, Michael Tees, Manish R. Patel, Krish Patel, Susan O'Brien, David A. Bond, Lindsey E. Roeker, Tanya Siddiqi, Michael L. Wang, Clare Sun, Omar Abdel-Wahab, Amanda Schwab, May Tan, Erin Meredith, Melissa A. Gessner, Su Young Kim, Adrian Wiestner, Alexey V Danilov
Publikováno v:
Blood. 140:2329-2332
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::24ab7e93f57da76c51ad8568023c5031
https://doi.org/10.1182/blood-2022-164772
https://doi.org/10.1182/blood-2022-164772
Autor:
McKensie A. Collins, In-Young Jung, Ziran Zhao, Kimberly Apodaca, Weimin Kong, Stefan Lundh, Joseph A. Fraietta, Arnon P. Kater, Clare Sun, Adrian Wiestner, J. Joseph Melenhorst
Publikováno v:
Cancer research communications, 2(9), 1089-1103
CD19-redirected chimeric antigen receptor (CAR) T cells have shown remarkable activity against B-cell cancers. While second-generation CARs induce complete remission in >80% of patients with acute lymphoblastic leukemia, similar monotherapy induces l
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cde7d05f94cb09796a19ee8e58a5f27e
https://doi.org/10.1158/2767-9764.crc-22-0200
https://doi.org/10.1158/2767-9764.crc-22-0200
Autor:
Adrian Wiestner, Maissa Mhibik, Tanja Nicole Hartmann, Elena Bibikova, Clare Sun, Inhye E. Ahn, Andy Itsara, Susan Soto, Pia Nierman, Sivasubramanian Baskar, Lita A. Freeman, Xin Tian, Pamela L. Tuma, Chingiz Underbayev, Erika M. Gaglione, Jonathan Chen, Anfal Alsadhan
Supplementary Figure S4. Clinical impact of CD49d bimodal expression on durability of BTKi therapy.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bc6e2f143a919314888e8db503217f33
https://doi.org/10.1158/1078-0432.23183864.v1
https://doi.org/10.1158/1078-0432.23183864.v1
Autor:
Adrian Wiestner, Maissa Mhibik, Tanja Nicole Hartmann, Elena Bibikova, Clare Sun, Inhye E. Ahn, Andy Itsara, Susan Soto, Pia Nierman, Sivasubramanian Baskar, Lita A. Freeman, Xin Tian, Pamela L. Tuma, Chingiz Underbayev, Erika M. Gaglione, Jonathan Chen, Anfal Alsadhan
Supplementary Table S6. DEGs for Baseline Comparison of CD49d+ and CD49d
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::150312c98f7abce27ddb7701ba534bab
https://doi.org/10.1158/1078-0432.23183837
https://doi.org/10.1158/1078-0432.23183837
Autor:
Adrian Wiestner, Maissa Mhibik, Tanja Nicole Hartmann, Elena Bibikova, Clare Sun, Inhye E. Ahn, Andy Itsara, Susan Soto, Pia Nierman, Sivasubramanian Baskar, Lita A. Freeman, Xin Tian, Pamela L. Tuma, Chingiz Underbayev, Erika M. Gaglione, Jonathan Chen, Anfal Alsadhan
Supplementary Methods
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8d9a64b4b25861d78576cc389c3aec03
https://doi.org/10.1158/1078-0432.23183858.v1
https://doi.org/10.1158/1078-0432.23183858.v1
Autor:
Adrian Wiestner, Maissa Mhibik, Tanja Nicole Hartmann, Elena Bibikova, Clare Sun, Inhye E. Ahn, Andy Itsara, Susan Soto, Pia Nierman, Sivasubramanian Baskar, Lita A. Freeman, Xin Tian, Pamela L. Tuma, Chingiz Underbayev, Erika M. Gaglione, Jonathan Chen, Anfal Alsadhan
Purpose:To determine the role of CD49d for response to Bruton's tyrosine kinase inhibitors (BTKi) in patients with chronic lymphocytic leukemia (CLL).Patients and Methods:In patients treated with acalabrutinib (n = 48), CD49d expression, VLA-4 integr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::aedb5e7d5092d8beaf29db3e171f1b4a
https://doi.org/10.1158/1078-0432.c.6664574.v1
https://doi.org/10.1158/1078-0432.c.6664574.v1
Autor:
Maissa Mhibik, Erika M Gaglione, David Eik, John Herrick, Janet Le, Inhye E Ahn, Christopher Chiu, Monica Wielgos-Bonvallet, Ida H Hiemstra, Esther CW Breij, Jenny Chen, Edward B Reilly, Pearlie K. Epling-Burnette, Edith Szafer Glusman, Clare Sun, Adrian Wiestner
Publikováno v:
Blood Advances.
Chronic lymphocytic leukemia (CLL) is an immunosuppressive disease characterized by increased infectious morbidity and inferior anti-tumor activity of immunotherapies. Targeted therapy with Bruton's tyrosine kinase inhibitors (BTKis), or the Bcl-2 in
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::dcae76acd97efcd6a93cfb0fc7587566
https://doi.org/10.1182/bloodadvances.2022009517
https://doi.org/10.1182/bloodadvances.2022009517